

Safe and Sustainable Innovation approaches and the role NAMs play – experience from Unilever


OECD SG SSIA, 24th Oct 23

Ian Malcomber

Head of Ingredient Stewardship

Safety & Environmental Assurance Centre

Unilever R&D





Unilever: We make many of the world's favourite brands

Over **400** brands

13 of the top **50**
consumer goods brands

14 brands with turnover over €1bn

Available in over **190** countries

3.4b people use our
products every day



dermalogica



CLEAR



AXE

LUX



Unilever's Safety & Environmental Assurance Centre (SEAC)

SEAC is Unilever's global centre of excellence in Safety & Sustainability Sciences

Diverse, multi-disciplinary team of ~150 scientists
based at Colworth, UK; ~70 miles north of London



Highly collaborative,
working with >70 academic, industry, government & NGO partners worldwide

Our purpose is to protect people & the environment by ensuring:

1 Unilever's products & innovations are **Safe & Sustainable by Design** without animal testing

2 Our scientists & capabilities are **industry-leading & we apply this to Unilever's Products & Brands**



3 Safety & Env. Sustainability **policies & regulations are based on modern science**



Safety without Animal Testing:


- **Unilever is committed to ending animal testing globally.** We believe in using science, not animals, to assure the safety of our products and their ingredients.
- **Non-animal safety approaches are applied by our multi-disciplinary scientists** in collaboration with world-class researchers & experts.
- These partnerships, combined with our expertise, **enable us to protect people and the environment without animal testing.**

<https://seac.unilever.com/our-science/safety-without-animal-testing/>




Systemic Safety

To understand the safety of ingredients if they are absorbed into the body (systemic safety), we do not use an animal study to...



Skin Allergy Safety

Some ingredients used in consumer products have the potential to cause allergic contact dermatitis (ACD), a type of skin allergy. To...




Inhalation Safety

A significant proportion of Unilever's products are aerosols and sprays which include underarm antiperspirants, hair sprays...



DART Safety

Developmental and reproductive toxicity (DART) refers to potential adverse effects that exposure to an ingredient may have on...



Immune Effects Safety

We consider all potential adverse impacts on the human immune system resulting from exposure to an ingredient. These include...




Microbiological Safety

Some of our consumer products have the potential to change the human microbiome or raise microbiological concerns...



Environmental Safety

Unilever ingredients are often disposed of down the drain after use, so it is important for us to assess the environmental safety of...



Biodegradation

Biodegradation is the process in which an ingredient is broken down through natural processes by microorganisms into simple substances...

Safe & Sustainable Innovation has long been embedded into Unilever

Safe and sustainable by design

How we build safety and environmental sustainability into every product innovation




We ensure that our products are safe for consumers and workers and have a positive impact on the environment.

Our Safety and Environmental Assurance Centre's (SEAC) industry-leading safety and environmental sustainability science has been developed and applied in partnership with external experts over many years. We use this science across Unilever, working with our colleagues to ensure that our products and processes are safe and sustainable by design and that our purpose-led brands can be confident in the statements they make about product and ingredient safety, health, environmental sustainability and the planet.


- Corporate Strategy provides the 'North Star'
- Brand strategy engagement on long term innovation needs
- Innovation programme review & influence
- Early & ongoing involvement in innovation projects (concept → post market launch)
- Guidance, digital systems & tools
- Corporate Code Policy (Responsible Innovation) & Standards

<https://www.unilever.com/planet-and-society/safety-and-environment/safe-and-sustainable-by-design/>

SSbD Frameworks in Development: EU



Unilever SSbD Case Study: Overview of typical safety and sustainability approaches used by Unilever throughout innovation stages for a biosurfactant



<https://seac.unilever.com/files/92ui5egz/production/6814727012110f78df6380f9d5d0f28c029218b4.pdf>



Unilever supports the development of Safe & Sustainable Innovation frameworks that drives a paradigm shift in the use of non-animal safety science and embeds environmental sustainability in chemical innovation

Our view on the priority challenges on the implementation of a SSbD Framework:




A paradigm shift is underway as use of non-animal safety science increases & safety assessment frameworks evolve to embed NGRA


Non-animal safety science is increasingly being used to make decisions on:

1. safety of **consumers** exposed to chemicals in **products**
2. safety of **workers** exposed to chemicals during product **manufacture**
3. safety of **people & non-human species** if exposed to chemicals in the **environment**


'Traditional' Risk Assessment



'Next Generation' Risk Assessment



Next Generation Risk Assessment (NGRA): aim is protection, not prediction of animal data



The hypothesis underpinning NGRA is that **if no bioactivity is observed at consumer-relevant concentrations, there can be no adverse health effects.**

At no point does NGRA attempt to predict the results of high dose toxicology studies in animals.


NGRA uses **new exposure science and understanding of human biology.**




Graph from Rusty Thomas EPA, with thanks. Rotroff et al (2010) Toxicological Sciences, **117**, 348-358

Unilever NGRA frameworks for Consumer Safety decisions

Developmental & Reproductive



Inhalation



Ongoing Evaluations

EPA and Unilever Announce Major Research Collaboration to Advance Non-animal Approaches for Chemical Risk Assessment

August 19, 2021

Contact Information
EPA Press Office: ozc@epa.gov


WASHINGTON - Today, the U.S. Environmental Protection Agency (EPA) and Unilever announced a collaborative agreement to explore better ways to assess chemical risks associated with consumer products. This agreement builds on prior cooperation between EPA and Unilever regarding New Approach Methods (NAMs), which are a promising alternative to conventional toxicity testing that are intended to reduce reliance on the use of animals.

EPA and Unilever have been jointly evaluating and using NAMs since 2015. This collaboration is helping EPA implement its New Approach Methods Work Plan and is the foundation for new efforts to demonstrate that these novel approaches can help decision makers better protect consumers, workers and the environment.

"EPA is a pioneer in developing and applying NAMs to identify and quantify risks to human health, while reducing the use of animals in chemical toxicity testing," said **H. Christopher Frey**, Deputy Assistant Administrator for Science Policy in EPA's Office of Research and Development. "We are excited to continue the collaboration with Unilever, which enhances the robustness of our mutual research to demonstrate the use of NAMs."


The new collaborative effort aims to establish a framework for the Next Generation of Risk Assessments based on NAMs. Such assessments are intended to quantify health risks to humans with sufficient scientific rigor to replace conventional animal based methods and to support EPA's mission to protect human health and the environment.

Skin Sensitisation



Reynolds et al (2021) *Reg Tox Pharmacol*, **127**, 105075

Systemic



Baltazar et al (2020) *Toxicol Sci*, **176**, 236-252

National Toxicology Program
U.S. Department of Health and Human Services

NICEATM News - 2021 Issue 25: May 27

In this Newsletter:

NICEATM to Collaborate with Unilever on Development of Predictive Model for Skin Sensitization

NICEATM to Collaborate with Unilever on Development of Predictive Model for Skin Sensitization


NICEATM has entered into an agreement with consumer products company Unilever to collaboratively test and further develop their Skin Allergy Risk Assessment (SARA) predictive model. SARA is a computational model that uses a variety of input data to estimate a probability that a chemical will cause an allergic skin reaction in humans. NICEATM will test the SARA model using a variety of chemical data sets, including chemicals of interest to U.S. and international regulatory agencies. NICEATM and Unilever will also work together to expand the SARA model to include data generated by NICEATM. The intent is to make the SARA model openly available for public use along with other NICEATM predictive models. Availability of the SARA model will help further reduce animal use for the endpoint of skin sensitization, and will improve upon existing efforts by providing points of departure for quantitative human risk assessment.

Information about other NICEATM projects to evaluate alternatives to animal use for skin sensitization is available at <https://ntp.niehs.nih.gov/qa/ACDtest>.

Reference: Reynolds et al. Probabilistic prediction of human skin sensitizer potency for use in next generation risk assessment. *Comput Toxicol* 9:36-49. <https://doi.org/10.1016/j.comtox.2018.10.004>





NGRA for Systemic Exposure & Effects through a hypothetical case study: 0.1% coumarin in face cream





Assumed that:

- Coumarin was 100% pure
- No *in vivo* data was available such as animal data, history of safe use (HoSU) or clinical data or use of animal data in read across



Key NAMs used in Coumarin case study

PBK Modelling



Toxicology in Vitro (2020), 63, 104746

In vitro pharmacological profiling

PERSPECTIVES

GUIDE TO DRUG DISCOVERY — OPINION

Reducing safety-related drug attrition: the use of *in vitro* pharmacological profiling


Joanne Brown, Andrew J. Brown, Jacques Huisman, Wolfgang Juratnik, Anne Gudim, Corwin Holzman and Steven Whittemore

Abstract (In vitro) pharmacological profiling is increasingly being used earlier in the drug discovery process to identify undesirable off-target activity profiles that could hinder or halt the development of a candidate drug or even lead to market withdrawal if discovered after a drug is approved. Here, for the first time, the rationale, strengths and methodologies for *in vitro* pharmacological profiling at four major pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Novartis and Pfizer) are presented and illustrated with examples of their impact on the drug discovery process. We hope that this will enable other companies and academic institutions to benefit from this knowledge and consider joining us in our collaborative knowledge sharing.

Decreasing the high attrition rate in the drug discovery and development process is a primary goal of the pharmaceutical industry. One of the main challenges in achieving this goal is making an appropriate balance between drug efficacy and potential side-effects. As well as possible in silico or *in vitro* safety-related activities, particularly for the key components of target clinical development. Gaining a better understanding of the safety profile of drug candidates early in the process is also crucial for reducing the attrition of drug candidates during the use of approved drugs, or even leading to their market withdrawal after being launched.

Early testing of drug candidates and are designed to prevent serious ADRs from occurring in clinical studies. The only *in vitro* pharmacology assay that is commonly required by regulatory authorities is one that measures the affinity of new chemical entities on the concentration of action (EC₅₀) on heterologously expressed human voltage-gated potassium channel subfamily 11 member 2 (hKv2.1), also known as hERG. The mechanism by which block of hERG can also potentially lead to other performance issues in patients following a prolongation of the QT interval is well characterized. The assessment of this ADR is one reason why the assay is a mandatory regulatory requirement. However, recent regulatory guidance has made it clear that targets should be included in *in vitro* pharmacological profiling as well as the range of the discovery process as well as *in vitro* pharmacological profiling should occur. Therefore, the general trend for most pharmaceutical companies is to perform the testing only in drug discovery to reduce attrition and to further target identification in the later stages of drug discovery and development.

Thus, for the first time, four major pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Novartis and Pfizer) share their knowledge and experience of the diverse range of testing, screening technologies to detect off-target activities of compounds. The objective of this article is to describe the rationale and main advantages of the use of *in vitro* pharmacological profiling to reduce the attrition of drug candidates during the drug discovery process.




eurofins | Cerep

Transcriptomics



- Use of full human gene panel ~ 21k
- 24 hrs exposure
- 7 concentrations
- 3 cell lines HepG2/ HepaRG/ MCF7
- 3D HepaRG spheroid

BMDexpress 2



Cellular Stress Pathways


- Exposure scenario adopted for chemical is 'low risk'** (from consumer goods perspective):
- Nicotinamide (Food, cosmetics)
 - Caffeine (Beverages, cosmetics)
 - Phenoxethanol (Cosmetics)
 - Sulfuraphane (Food)
 - BHQ (Antioxidant)
 - Triclosan (Antimicrobial)
- Exposure scenario adopted for chemical is 'high risk'** (from consumer goods perspective):
- CDO-Me (Drug)
 - DEM (Industrial chemical)
 - Doxorubicin (Drug)
 - Diclofenac (Drug)
 - Troglitazone (Drug)
 - Pioglitazone (Drug)
 - Rosiglitazone (Drug)



Toxicol Sci (2020), 176, 11-33

NGRA for Systemic Exposure & Effects: 0.1% coumarin in face cream

Determine
Margin of
Safety



The 5th percentile of the MoS
distribution ranged between
706 and 96738

In this case study:

- **Weight of evidence suggested that the inclusion of 0.1% coumarin in face cream is safe for the consumer**

Baltazar et al., (2020) *Tox Sci* Volume 176, Issue 1, 236–252


What we would like to see in Safe & Sustainable Innovation frameworks

- Acceptance of NAMs tools & approaches allowing flexibility in their use to account for the specifics of the assessment being conducted
- Safety assessed for defined uses considering exposure & any risk management measures (not hazard alone)
 - Example: Enzymes in laundry detergents
- Approaches for considering Trade-offs

Challenge: How to use the latest human relevant safety science in Safe and Sustainable Innovation frameworks that rely on Classification & Labelling criteria based on traditional animal studies?

Acknowledgements to many Unilever colleagues especially Carl Westmoreland and Gavin Maxwell

Thank You



seac.unilever.com